SynthesisAnaerobe2022
The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis.
Synthesis in Anaerobe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Trends in Clostridioides difficile infection prevalence among pediatric cancer patients: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Pooled it
- Antimicrobial stewardship challenges during the COVID-19 pandemic: implications of antibiotic overuse and antimicrobial resistance.Arhiv za higijenu rada i toksikologiju · 2026Review
- Twenty-Five-Year Trends in Mortality Associated withMedical sciences (Basel, Switzerland) · 2026Article
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2026Article
- Incidence of hospital-acquired toxin-producing clostridioides difficile infection between the pre-pandemic (2017-2019) and pandemic (2020-2022): a retrospective cohort study.Archives of public health = Archives belges de sante publique · 2026Article
- Significant Increase inGastro hep advances · 2026Article
- Burden of Healthcare-Associated Infections on Mortality Among COVID-19 Hospitalized Patients.Journal of clinical medicine · 2025Article
- Antibiotic Usage and Healthcare-AssociatedAntibiotics (Basel, Switzerland) · 2025Article
- Article
- COVID-19 andAntibiotics (Basel, Switzerland) · 2024Article
- Editorial:Frontiers in medicine · 2024Article
- Article
- Effect of the COVID-19 Pandemic on Rates and Epidemiology ofAntibiotics (Basel, Switzerland) · 2023Article
- COVID-19 andInfectious disease reports · 2023Article
- Clostridium difficile Infection Rates During the Pandemic in New York Capital Area: A Single-Center Study.Cureus · 2023Article
- Diarrhea and Coronavirus Disease 2019 Infection.Gastroenterology clinics of North America · 2023Review
- Article
- The impact of the COVID-19 pandemic onTherapeutic advances in gastroenterology · 2023Review
- Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 andBiomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe main aim of this systematic review and meta-analysis was to assess the proportion of confirmed COVID-19 patients with Clostridioides difficile infection (CDI) and to describe risk factors and outcome of these patients.
methodsMEDLINE and Cochrane Central Register of Controlled Trials databases were searched up to July 15, 2021. We included studies reporting data on CDI occurring in patients with a confirmed diagnosis of COVID-19. We pooled proportion of CDI patients using a random effects model (DerSimonian-Laird method) stabilising the variances using the Freeman-Tukey double arcsine transformation.
resultsThirteen studies were included in the systematic review. All the studies retrospectively collected data between February 2020 and February 2021. The reported CDI incidence rates ranged from 1.4 to 4.4 CDI cases per 10,000 patient-days. Seven studies reported data on the number of COVID-19 patients who developed CDI and the total number of COVID-19 patients in the study period and were included in the meta-analysis, comprising 23,697 COVID-19 patients. The overall pooled proportion of COVID-19 patients who had CDI was 1% [95% confidence interval: 1-2]. Among studies reporting CDI occurrence in patients with and without COVID-19, the majority of them reported reduced or unchanged CDI rates compared to pre-COVID period.
conclusionsCDI is a relevant issue for COVID-19 patients. Adherence to infection prevention and control measures and to the antimicrobial stewardship principles is crucial even during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.